<?xml version="1.0" encoding="UTF-8"?>
<ref id="B163-biomedicines-08-00060">
 <label>163.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Curti</surname>
    <given-names>B.D.</given-names>
   </name>
   <name>
    <surname>Richards</surname>
    <given-names>J.M.</given-names>
   </name>
   <name>
    <surname>Hallmeyer</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Faries</surname>
    <given-names>M.B.</given-names>
   </name>
   <name>
    <surname>Andtbacka</surname>
    <given-names>R.H.I.</given-names>
   </name>
   <name>
    <surname>Daniels</surname>
    <given-names>G.A.</given-names>
   </name>
   <name>
    <surname>Grose</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Shafren</surname>
    <given-names>D.</given-names>
   </name>
  </person-group>
  <article-title>Activity of a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients previously treated with anti-PD1 blockade therapy</article-title>
  <source>J. Clin. Oncol.</source>
  <year>2017</year>
  <volume>35</volume>
  <fpage>3014</fpage>
  <pub-id pub-id-type="doi">10.1200/JCO.2017.35.15_suppl.3014</pub-id>
 </element-citation>
</ref>
